[Federal Register Volume 61, Number 244 (Wednesday, December 18, 1996)]
[Notices]
[Page 66675]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 96-32033]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
[Docket No. 96E-0380]
Determination of Regulatory Review Period for Purposes of Patent
Extension; VISTIDETM
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) has determined the
regulatory review period for VISTIDETM and is publishing this
notice of that determination as required by law. FDA has made the
determination because of the submission of an application to the
Commissioner of Patents and Trademarks, Department of Commerce, for the
extension of a patent which claims that human drug product.
ADDRESSES: Written comments and petitions should be directed to the
Dockets Management Branch (HFA-305), Food and Drug Administration,
12420 Parklawn Dr., rm. 1-23, Rockville, MD 20857.
FOR FURTHER INFORMATION CONTACT: Brian J. Malkin, Office of Health
Affairs (HFY-20), Food and Drug Administration, 5600 Fishers Lane,
Rockville, MD 20857, 301-443-1382.
SUPPLEMENTARY INFORMATION: The Drug Price Competition and Patent Term
Restoration Act of 1984 (Pub. L. 98-417) and the Generic Animal Drug
and Patent Term Restoration Act (Pub. L. 100-670) generally provide
that a patent may be extended for a period of up to 5 years so long as
the patented item (human drug product, animal drug product, medical
device, food additive, or color additive) was subject to regulatory
review by FDA before the item was marketed. Under these acts, a
product's regulatory review period forms the basis for determining the
amount of extension an applicant may receive.
A regulatory review period consists of two periods of time: A
testing phase and an approval phase. For human drug products, the
testing phase begins when the exemption to permit the clinical
investigations of the drug becomes effective and runs until the
approval phase begins. The approval phase starts with the initial
submission of an application to market the human drug product and
continues until FDA grants permission to market the drug product.
Although only a portion of a regulatory review period may count toward
the actual amount of extension that the Commissioner of Patents and
Trademarks may award (for example, half the testing phase must be
subtracted as well as any time that may have occurred before the patent
was issued), FDA's determination of the length of a regulatory review
period for a human drug product will include all of the testing phase
and approval phase as specified in 35 U.S.C. 156(g)(1)(B).
FDA recently approved for marketing the human drug product
VISTIDETM (cidofovir). VISTIDETM is indicated for the
treatment of CMV retinitis in patients with acquired immune deficiency
syndrome (AIDS). Subsequent to this approval, the Patent and Trademark
Office received a patent term restoration application for
VISTIDETM (U.S. Patent No. 5,142,051) from the Institute of
Organic Chemistry & Biochemistry of the Academy of Science of the Czech
Republic and Rega Institut, and the Patent and Trademark Office
requested FDA's assistance in determining this patent's eligibility for
patent term restoration. In a letter dated October 24, 1996, FDA
advised the Patent and Trademark Office that this human drug product
had undergone a regulatory review period and that the approval of
VISTIDETM represented the first permitted commercial marketing or
use of the product. Shortly thereafter, the Patent and Trademark Office
requested that FDA determine the product's regulatory review period.
FDA has determined that the applicable regulatory review period for
VISTIDETM is 1,533 days. Of this time, 1,266 days occurred during
the testing phase of the regulatory review period, while 267 days
occurred during the approval phase. These periods of time were derived
from the following dates:
1. The date an exemption under section 505(i) of the Federal Food,
Drug, and Cosmetic Act (21 U.S.C. 355(i)) became effective: April 17,
1992. The applicant claims April 16, 1992, as the date the
investigational new drug application (IND) became effective. However,
FDA records indicate that the IND's effective date was April 17, 1992,
which was 30 days after FDA received the IND on March 18, 1992.
2. The date the application was initially submitted with respect to
the human drug product under section 505(b) of the Federal Food, Drug,
and Cosmetic Act: October 4, 1995. The applicant claims September 29,
1995, as the date the new drug application (NDA) for VISTIDETM
(NDA 20-638) was initially submitted. However, FDA records indicate
that NDA 20-638 was submitted on October 4, 1995.
3. The date the application was approved: June 26, 1996. FDA has
verified the applicant's claim that NDA 20-638 was approved on June 26,
1996.
This determination of the regulatory review period establishes the
maximum potential length of a patent extension. However, the U.S.
Patent and Trademark Office applies several statutory limitations in
its calculations of the actual period for patent extension. In its
application for patent extension, the applicant seeks 305 days of
patent term extension.
Anyone with knowledge that any of the dates as published is
incorrect may, on or before February 18, 1997 submit to the Dockets
Management Branch (address above) written comments and ask for a
redetermination. Furthermore, any interested person may petition FDA,
on or before June 17, 1997 for a determination regarding whether the
applicant for extension acted with due diligence during the regulatory
review period. To meet its burden, the petition must contain sufficient
facts to merit an FDA investigation. (See H. Rept. 857, part 1, 98th
Cong., 2d sess., pp. 41-42, 1984.) Petitions should be in the format
specified in 21 CFR 10.30.
Comments and petitions should be submitted to the Dockets
Management Branch (address above) in three copies (except that
individuals may submit single copies) and identified with the docket
number found in brackets in the heading of this document. Comments and
petitions may be seen in the Dockets Management Branch between 9 a.m.
and 4 p.m., Monday through Friday.
Dated: December 4, 1996.
Stuart L. Nightingale,
Associate Commissioner for Health Affairs.
[FR Doc. 96-32033 Filed 12-17-96; 8:45 am]
BILLING CODE 4160-01-F
